Table 9 Adjuvant chemotherapy and adjuvant trastuzumab by tumour and patient characteristics in HER2-positive pT1a and pT1b breast cancers (n = 49)
From: Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study
All HER2-positive tumours | HER2-positive tumours treated with adjuvant chemotherapy* | HER2-positive tumours treated with adjuvant chemotherapy and trastuzumab * | |
|---|---|---|---|
No. of patients | 49 | 36 (73.5%) | 30 (61.2%) |
Menopausal status | |||
pre- | 19 | 18 (94.7%) | 14 (73.7%) |
post- | 30 | 18 (60.0%) | 16 (53.3%) |
Age (years) | |||
18–34 | 2 | 2 (100.0%) | 2 (100.0%) |
35–49 | 17 | 17 (100.0%) | 12 (70.6%) |
50–69 | 25 | 16 (64.0%) | 15 (60.0%) |
≥ 70 | 5 | 1 (20.0%) | 1 (20.0%) |
Hormonal receptor status | |||
positive | 29 | 18 (62.1%) | 15 (51.7%) |
negative | 20 | 18 (90.0%) | 15 (75.0%) |
LN status | |||
pN0 | 43 | 30 (69.7%) | 24 (55.8%) |
pN1 | 4 | 4 (100.0%) | 4 (100.0%) |
pN2 | 2 | 2 (100.0%) | 2 (100.0%) |
Grading | |||
G1 | 2 | 1 (50.0%) | 0 (0.0%) |
G2 | 23 | 16 (69.6%) | 13 (56.5%) |
G3 | 19 | 16 (84.2%) | 16 (84.2%) |